Zogenix’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Dravet Syndrome

 Zogenix’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Dravet Syndrome

Zogenix’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Dravet Syndrome

Shots:

  • The US FDA’s approval is based on two P-III studies assessing Fintepla vs PBO in patients aged ≥2yrs. with Dravet syndrome and a safety data from an OLE trial in which many patients received Fintepla for up to 3yrs.
  • In addition to the existing treatment regimens, the therapy demonstrated a reduction in the frequency of monthly convulsive seizure in patients whose seizures were not controlled on one or more antiepileptic drugs
  • The company will launch the therapy through restricted distribution program, called the Fintepla REMS Program, and is expected to be available through Zogenix’s specialty pharmacy partner by July’20

Click here to read full press release/ article | Ref: Zogenix | Image: Zogenix

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post